Abstract: Benzodiazepine derivatives are disclosed that act as potent inhibitors of ras farnesyl:protein transferase. Pharmaceutical compositions containing these benzodiazepines are provided for treatment of diseases for which inhibition of the ras farnesyl:protein transferase is indicated.
Type:
Grant
Filed:
October 25, 1994
Date of Patent:
July 2, 1996
Assignees:
Genentech, Inc., Board of Regents, The University of Texas System
Inventors:
James C. Marsters, Jr., Michael S. Brown, Craig W. Crowley, Joseph L. Goldstein, Guy L. James, Robert S. McDowell, David Oare, Thomas E. Rawson, Mark Reynolds, Todd C. Somers
Abstract: A peptide containing the tripeptide recognition sequences RGD or KGD in a cycle and an exocyclic group bearing a positive charge is provided. The compound is provided in therapeutic form for administration to a mammal and exhibits high specificity and potency as a platelet aggregation inhibitor without undesireable side effects.
Type:
Grant
Filed:
September 23, 1994
Date of Patent:
February 20, 1996
Assignee:
Genentech, Inc.
Inventors:
John P. Burnier, Thomas Gadek, Robert S. McDowell
Abstract: A trycylic benzodiazepine derivative which acts as a nonpeptidyl platelet aggregation inhibitor is provided. This inhibitor potently inhibits fibrinogen binding to the GPII.sub.b III.sub.a receptor and is provided in therapeutic compositions for the treatment of diseases for which blocking platelet aggregation is indicated. These nonpeptidyl inhibitors are provided in combination with thrombolytics and anticoagulants.
Type:
Grant
Filed:
July 29, 1993
Date of Patent:
February 20, 1996
Assignee:
Genentech, Inc.
Inventors:
Brent K. Blackburn, Kirk Robarge, Todd C. Somers
Abstract: A benzazepine derivative that acts as a nonpeptidyl platelet aggregation inhibitor is provided. This inhibitor potently inhibits fibrinogen binding to the GPII.sub.b III.sub.a receptor and is provided in therapeutic compositions for the treatment of diseases for which blocking platelet aggregation is indicated. These nonpeptidyl inhibitors are provided in combination with thrombolytics and anticoagulants.
Type:
Grant
Filed:
May 6, 1993
Date of Patent:
April 4, 1995
Assignee:
Genentech, Inc.
Inventors:
Brent Blackburn, Robert McDowell, Thomas Gadek, Rob Webb
Abstract: 5,6-Dehydronorketamine and derivatives retaining the .alpha.,.beta.-unsaturated carbonyl are disclosed. These end other Michael or Michael-type acceptors and adducts are shown to influence the replication, differentiation or maturation of blood cells, especially platelet progenitor cells. Accordingly, these compounds are used for treatment of thrombocytopenia.
Abstract: The invention in its broad aspects relates to peptide derivatives which are useful as inhibitors platelet function mediated by the GP llbllla receptor and for the prevention of thrombus formation. The compounds of this invention are shown by the following Formula I: ##STR1## and the pharmaceutically acceptable salts thereof.
Type:
Grant
Filed:
July 17, 1989
Date of Patent:
January 24, 1995
Assignee:
Genentech, Inc.
Inventors:
Peter L. Barker, John P. Burnier, Eugene D. Thorsett
Abstract: A tissue factor protein mutant capable of neutralizing the ability of endogenous tissue factor to induce coagulation is provided. A representative tissue factor mutant designated K165A, K166A TF is useful in a method for inhibiting thrombin-induced platelet aggregation in a mammal, either separately or in combination with a thrombolytic agent, an anticoagulant, or a GPII.sub.b III.sub.a inhibitor.
Abstract: A benzodiazepinedione derivative which acts as a nonpeptidyl platelet aggregation inhibitor is provided. This inhibitor potently inhibits fibrinogen binding to the GPII.sub.b III.sub.a receptor and is provided in therapeutic compositions for the treatment of diseases for which blocking platelet aggregation is indicated. These nonpeptidyl inhibitors are provided in combination with thrombolytics and anticoagulants.
Type:
Grant
Filed:
April 10, 1992
Date of Patent:
October 5, 1993
Assignee:
Genentech, Inc.
Inventors:
Brent Blackburn, Robert McDowell, Thomas Gadek, Peter Barker, Lawrence McGee, Rob Webb
Abstract: 5,6-Dehydronorketamine and derivatives retaining the .alpha.,.beta.-unsaturated carbonyl are disclosed. These and other Michael or Michael-type acceptors and adducts are shown to influence the replication, differentiation or maturation of blood cells, especially platelet progenitor cells. Accordingly, these compounds are used for treatment of thrombocytopenia.
Abstract: A composition of matter derived from hematophagous leech comprising specified purified amino acid sequences represented by the general formula:CXXXRGDXXXXC(Seq. ID No. 11)and capable of functioning as an antithrombotic by inhibiting the binding of fibrinogen to the platelet glycoprotein II.sub.b III.sub.a (GP II.sub.b III.sub.a), a fibrinogen receptor. Methods for the purification of amino acid sequences from leeches, and particularly from leeches of the genus Macrobdella and Placobdella. are provided. Isolated nucleic acid sequences encoding these amino acid sequences; an expression vector containing the isolated nucleic acid; and a cell containing the expression vector are also described. A process for chemical synthesis of the amino acid sequences and a method for reducing platelet aggregation in a mammal by administering a composition containing the amino acid sequences to the mammal in a pharmaceutically effective amount are provided.
Abstract: A screening method for the selection of mutagenized proteins that are normally secreted by cells is described. The method includes the development of a cloning vector for the expression of secretory proteins as fusion proteins on the cell surface of transfected mammalian cells. The secreted protein is displayed on the cell surface by fusion with the glycophospholipid membrane anchor of decay accelerating factor (DAF). Tissue-type plasminogen activator (t-PA), which is normally secreted, is used as a model protein. PCR mutagenesis is used to generate random mutations within the Kringle 1 (K1) domain of t-PA. Fluorescence activated cell sorting (FACS) is employed to screen for t-PA mutants possessing a loss of an epitope to a specific Mab, whose nonlinear binding domains overlap with the t-PA clearance receptor contact regions novel t-PA mutants designated N115S, N1425S, and K159R were discovered by this method.
Type:
Grant
Filed:
July 11, 1991
Date of Patent:
June 29, 1993
Assignee:
Genentech, Inc.
Inventors:
David V. Goeddel, Glenn C. Rice, David W. H. Leung
Abstract: Pyridinone or pyrimidinone nucleoside bases containing fused aromatic polycyclic rings are provided. These polycyclic nucleosides are incorporated into oligonucleotides and hybridized to complementary nucleic acid. Fluorescence spectroscopy and thermal denaturation profiles provided evidence that the polycyclic base is intercalated into the resulting duplex. The fused polycyclic ring systems optionally are substituted with reactive species which inactivate complementary nucleic acids. The oligonucleotides of this invention are useful as improved probes, diagnostic reagents, or for cleaving or derivatizing predetermined domains within nucleic acids.
Type:
Grant
Filed:
July 1, 1988
Date of Patent:
December 29, 1992
Assignee:
Genentech, Inc.
Inventors:
Norbert W. Bischofberger, Mark D. Matteucci
Abstract: A chimeric amino acid analogue is provided suitable for incorporating into peptides which compound is represented by Formula 1: ##STR1## where P.sub.1 is preferably an amine protecting agent, and P.sub.2 and P.sub.3 are preferably amine or guanidine protecting agents. X can be OH, halide, or preferably an activating group suitable for conjugating the compound of Formula 1 to a peptide by conventional means, and m and n are 0-1 and 0-2 respectively.Peptides containing the chimeric amino acid analog are provided and include a platelet-aggregation inhibitor represented byAaa.sub.1 -CPdl-Gly-Asp-Aaa.sub.2where Aaa.sub.1 is Gly or H, Cpdl is the compound of Formula 1 which has been deprotected and Aaa.sub.2 is a hydrophobic amino acid preferably Val.
Abstract: A method and therapeutic composition for the treatment of bleeding disorders, for example those characterized by a tendency toward hemorrhage or a hypercoagulative state, by the administration of tissue factor protein or antagonists thereof.